Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2015
Συγγραφείς:
Kastritis, Efstathios Roussou, Maria Gavriatopoulou, Maria Migkou, Magdalini Kalapanida, Despina Pamboucas, Constantinos Kaldara, Elisavet Ntalianis, Argyrios Psimenou, Erasmia Toumanidis, Savvas T others
